Evidence map›Paper›PMID 27377825›Full record

ReviewJournal of surgical oncology2016

The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.

Muhammad Kashif Riaz, Susan Bal, Trisha Wise-Draper

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muhammad Kashif RiazDivision of Hematology/Oncology, University of Cincinnati Medical Center, Cincinnati, Ohio.
Susan BalDivision of Hematology/Oncology, University of Cincinnati Medical Center, Cincinnati, Ohio.
Trisha Wise-DraperAssistant Professor of Medicine, Division of Hematology/Oncology, Head and Neck Oncology/Experimental Therapeutics, Associate Hematology/Oncology Fellowship Director, University of Cincinnati Cancer Institute, Cincinnati, Ohio.

Funding

KL2 Training ProgramKL2TR001426 · NCATS · UNIVERSITY OF CINCINNATI · PI ZELLER, MARGARET H · 2015 to 2024
$6.8M
NCATS NIH HHS KL2 TR001426
6 · The paper itself

Abstract

Metastatic cancer remains a devastating disease that threatens to disrupt entire family structures creating economic and psychosocial stress. Fortunately, great strides have resulted in improved therapies over the years but at a huge social-economic cost. The economic burden has risen greatly and carries with it new ethical concerns when deciding treatment. Here, we discuss the financial and ethical challenges that oncologists and their patients face in the era of novel treatment strategies. J. Surg. Oncol. 2016;114:323-328. © 2016 Wiley Periodicals, Inc.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisHealth Care CostsHumansNeoplasm MetastasisPatient SelectionQuality-Adjusted Life YearsQuality of LifeRisk Assessmentchemotherapycost effectivenessmetastatic cancer

Identifiers

PMID27377825
PMCPMC5867536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.